Key Developed Gastrointestinal Therapeutics Markets Examined by GBI Research in In-demand Report Published at MarketPublishers.com
10 Feb 2014 • by Natalie Aster
LONDON – As of 2012, the value of the market for gastrointestinal therapeutics in major developed nations was estimated at USD 6.8 billion. Through 2019, the figure is forecast to decline at 0.3% CAGR. In 2012, the value of the irritable bowel syndrome market reached USD 727 million, and it is forecast to grow at a CAGR of nearly 14.5% through 2019. The ulcerative colitis market value approached USD 2.2 billion in the same year, and it is expected to post a CAGR of 6% during the forecast period. The market for Crohn’s disease was valued at around USD 4 billion, with its value projected to decline at 7.5% CAGR over the forecasted period.
In-demand report “Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries” worked out by GBI Research provides keen insights into in the gastrointestinal therapeutics market in the leading developed markets – the USA, France, the UK, Germany, Spain, Italy, Canada, and Japan.
The report provides detailed research and analysis of the three major gastrointestinal therapeutic indications, such as irritable bowel syndrome, ulcerative colitis, and Crohn’s disease. It gives a deep overview of the disease, covering its epidemiology, as well as various treatment patterns and algorithms. The study sheds light on the major marketed drug products for the three indication types, besides presenting in-depth pipeline analysis. The top licensing and co-development agreements for IBS, UC and CD by geography are thoroughly discussed. The study identifies the essential driving forces and restraining factors that are likely to greatly impact the overall gastrointestinal therapeutics marketplace in the years ahead. The report provides granular market size estimates and forecasts from 2012 to 2019.
Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries Published: January, 2014
Price: US$ 3,500.00
Other In-demand Reports by GBI Research Include:
- Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation
- Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management
- Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
More in-demand and new studies by the publisher can be found at GBI Research Research page.